(Q36738171)

16 August 2017

1 reference

title

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review (English)

1 reference

16 August 2017

1 reference

1 reference

C L Cooper

1

1 reference

16 August 2017

R P G van Heeswijk

series ordinal

2

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

1-7

1 reference

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Race is not associated with nevirapine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Position paper on therapeutic drug monitoring of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Incidence and risk factors for nevirapine-associated rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

The relationship between nevirapine plasma concentrations and abnormal liver function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00426.X

10.1111/J.1468-1293.2007.00426.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference